[go: up one dir, main page]

SE9804022D0 - Use of a parvovirus capsid particles in the inhibition of hematopoietic progenitor cells - Google Patents

Use of a parvovirus capsid particles in the inhibition of hematopoietic progenitor cells

Info

Publication number
SE9804022D0
SE9804022D0 SE9804022A SE9804022A SE9804022D0 SE 9804022 D0 SE9804022 D0 SE 9804022D0 SE 9804022 A SE9804022 A SE 9804022A SE 9804022 A SE9804022 A SE 9804022A SE 9804022 D0 SE9804022 D0 SE 9804022D0
Authority
SE
Sweden
Prior art keywords
cells
parvovirus capsid
inhibition
hematopoietic progenitor
progenitor cells
Prior art date
Application number
SE9804022A
Other languages
Swedish (sv)
Other versions
SE9804022L (en
SE520177C2 (en
Inventor
Kristina Broliden
Magnus Westgren
Original Assignee
Kristina Broliden
Mestgren Magnus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kristina Broliden, Mestgren Magnus filed Critical Kristina Broliden
Priority to SE9804022A priority Critical patent/SE520177C2/en
Publication of SE9804022D0 publication Critical patent/SE9804022D0/en
Priority to CA002352043A priority patent/CA2352043A1/en
Priority to PCT/IB1999/002112 priority patent/WO2000030668A2/en
Priority to JP2000583551A priority patent/JP2003516927A/en
Priority to AU25666/00A priority patent/AU2566600A/en
Priority to KR1020017006374A priority patent/KR20010080518A/en
Priority to MXPA01004949A priority patent/MXPA01004949A/en
Priority to CZ20011369A priority patent/CZ20011369A3/en
Priority to HU0104298A priority patent/HUP0104298A2/en
Priority to CN99813653A priority patent/CN1328469A/en
Priority to PL99348640A priority patent/PL348640A1/en
Priority to EP99968407A priority patent/EP1131085A2/en
Publication of SE9804022L publication Critical patent/SE9804022L/en
Priority to IS5931A priority patent/IS5931A/en
Priority to NO20012534A priority patent/NO20012534L/en
Priority to US09/991,433 priority patent/US6818612B2/en
Priority to US10/200,616 priority patent/US6743772B1/en
Publication of SE520177C2 publication Critical patent/SE520177C2/en
Priority to US10/792,640 priority patent/US20060141477A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention described herein relates to the discovery of methods and compositions for the inhibition of growth and/or migration of cells that have the P antigen, including but not limited to, cells of hematopoietic origin and endothelial cells. More specifically, parvovirus capsid particles or fragments of parvovirus capsid proteins are used to manufacture medicaments that can be administered to a subject to inhibit hematopoietic progenitor cell growth (e.g., prior to stem cell transplantation), endothelial cell growth, (e.g., as an anti-tumorigenesis treatment or to prevent restenosis or fibrotic build up following prosthetic implantation), or to prevent disorders that involve the abnormal proliferation of cells that have the P antigen (e.g., polycytemia vera).
SE9804022A 1998-11-24 1998-11-24 Use of empty, non-infectious, recombinant parvoviral capsid particles, or β-antigen-blocking portions thereof, for the manufacture of drugs for inhibiting hematopoietic stem cells SE520177C2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE9804022A SE520177C2 (en) 1998-11-24 1998-11-24 Use of empty, non-infectious, recombinant parvoviral capsid particles, or β-antigen-blocking portions thereof, for the manufacture of drugs for inhibiting hematopoietic stem cells
EP99968407A EP1131085A2 (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
HU0104298A HUP0104298A2 (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
PL99348640A PL348640A1 (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
JP2000583551A JP2003516927A (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in inhibiting cell growth and migration
AU25666/00A AU2566600A (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
KR1020017006374A KR20010080518A (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
MXPA01004949A MXPA01004949A (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration.
CZ20011369A CZ20011369A3 (en) 1998-11-24 1999-11-23 Use of B 19 parvovirus empty, non-infectious, recombinant capsid particles in the inhibition of cell proliferation and migration, patient treatment methods and inhibition of fibrotic build up, kit, medicinal drug and use of the B 19 parvovirus capsids
CA002352043A CA2352043A1 (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
CN99813653A CN1328469A (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles to inhibit cell proliferation and migration
PCT/IB1999/002112 WO2000030668A2 (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
IS5931A IS5931A (en) 1998-11-24 2001-05-02 Use of small virus coatings to inhibit cell proliferation and cell migration
NO20012534A NO20012534L (en) 1998-11-24 2001-05-23 Use of parvoviral capsid particles in the inhibition of cell proliferation and migration
US09/991,433 US6818612B2 (en) 1998-11-24 2001-11-16 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
US10/200,616 US6743772B1 (en) 1998-11-24 2002-07-19 Use of parovirus capsid particles in the inhibition of cell proliferation and migration
US10/792,640 US20060141477A1 (en) 1998-11-24 2004-03-02 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804022A SE520177C2 (en) 1998-11-24 1998-11-24 Use of empty, non-infectious, recombinant parvoviral capsid particles, or β-antigen-blocking portions thereof, for the manufacture of drugs for inhibiting hematopoietic stem cells

Publications (3)

Publication Number Publication Date
SE9804022D0 true SE9804022D0 (en) 1998-11-24
SE9804022L SE9804022L (en) 2000-05-25
SE520177C2 SE520177C2 (en) 2003-06-03

Family

ID=20413393

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804022A SE520177C2 (en) 1998-11-24 1998-11-24 Use of empty, non-infectious, recombinant parvoviral capsid particles, or β-antigen-blocking portions thereof, for the manufacture of drugs for inhibiting hematopoietic stem cells

Country Status (14)

Country Link
EP (1) EP1131085A2 (en)
JP (1) JP2003516927A (en)
KR (1) KR20010080518A (en)
CN (1) CN1328469A (en)
AU (1) AU2566600A (en)
CA (1) CA2352043A1 (en)
CZ (1) CZ20011369A3 (en)
HU (1) HUP0104298A2 (en)
IS (1) IS5931A (en)
MX (1) MXPA01004949A (en)
NO (1) NO20012534L (en)
PL (1) PL348640A1 (en)
SE (1) SE520177C2 (en)
WO (1) WO2000030668A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE345352T1 (en) 2001-07-10 2006-12-15 Deutsches Krebsforsch COMPOSITION OF A PARVOVIRUS VP1 PROTEIN VARIANT AND AN ARVOVIRUS NS1 PROTEIN FOR INDUCING CYTOLYSIS
ATE465173T1 (en) 2004-09-24 2010-05-15 Intercell Ag ALTERED VP-1CAPSID PROTEIN FROM PARVOVIRUS B19
CN101475942B (en) * 2008-11-28 2012-05-23 中国人民解放军第四军医大学 B19 virus VP1 unique region gene
WO2012159006A2 (en) * 2011-05-18 2012-11-22 University Of Florida Research Foundation, Inc. Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002839C (en) * 1988-11-14 2000-10-10 Neal S. Young Parvovirus capsids
NL8902301A (en) * 1989-09-14 1991-04-02 Rijksuniversiteit HUMAN PARVOVIRUS B19 PROTEINS, THEIR PRODUCTION AND THEIR USE IN DIAGNOSTIC ASSAYS AND VACCINES.

Also Published As

Publication number Publication date
MXPA01004949A (en) 2003-03-10
SE9804022L (en) 2000-05-25
SE520177C2 (en) 2003-06-03
NO20012534L (en) 2001-06-29
CN1328469A (en) 2001-12-26
AU2566600A (en) 2000-06-13
WO2000030668A8 (en) 2000-09-14
WO2000030668A2 (en) 2000-06-02
HUP0104298A2 (en) 2002-03-28
EP1131085A2 (en) 2001-09-12
CA2352043A1 (en) 2000-06-02
IS5931A (en) 2001-05-02
JP2003516927A (en) 2003-05-20
NO20012534D0 (en) 2001-05-23
PL348640A1 (en) 2002-06-03
CZ20011369A3 (en) 2001-10-17
KR20010080518A (en) 2001-08-22
WO2000030668A9 (en) 2001-04-05
WO2000030668A3 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
Jia et al. Deferoxamine released from poly (lactic‐co‐glycolic acid) promotes healing of osteoporotic bone defect via enhanced angiogenesis and osteogenesis
Murata et al. Acid‐insoluble human dentin as carrier material for recombinant human BMP‐2
Lynn et al. Temporal progression of the host response to implanted poly (ethylene glycol)‐based hydrogels
DK1082410T3 (en) Human CD45 and / or fibroblast mesenchymal stem cells
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
PT1062321E (en) UTILIZATIONS FOR HUMAN MESENQUIMIAL NON-AUTOMATIC STEM CELLS
DE60103052D1 (en) USE OF CXCR4 ANTAGONISTS FOR TREATING CANCER AND AUTOIMMUNE DISEASES
ATE440602T1 (en) NICOTINE RECEPTOR AGONISTS IN STEM CELLS AND PROGRESSOR CELL INDUCTION
NZ527565A (en) Methods and devices for tissue repair
BR0315645A (en) Actrib fusion polypeptides and their uses
DE69924715D1 (en) USE OF ANGIOTENSIN ANALOGUE FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING OVERLAPPING OF WHITE BLOOD CELLS AND MOBILIZING HAEMATOPOIETIC STEM CELLS AFTER CHEMOTHERAPEUTIC TREATMENT
ATE256195T1 (en) CYTOPATIC VIRUSES FOR THE THERAPY AND PROPHYLAXIS OF NEOPLASIA
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2002069988A3 (en) Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and their use in bone marrow transplantation
Huang et al. Icariin inhibits chondrocyte apoptosis and angiogenesis by regulating the TDP‐43 signaling pathway
DE69333931D1 (en) Use of Krillenzymen for the treatment of dental plaque
IL115473A (en) Pharmaceutical compositions and compounds for inhibition of stem cell proliferation, use of such compounds in the manufacture of medicaments for this purpose, and in vitro methods for treating bone marrow and for preparing hematopoietic cells for therapy
Hynes et al. Potential of iPSC‐derived mesenchymal stromal cells for treating periodontal disease
NO20035434D0 (en) Treatment or prophylaxis of transplant rejection of insulin-producing cells
Gong et al. Lentiviral‐mediated expression of SATB 2 promotes osteogenic differentiation of bone marrow stromal cells in vitro and in vivo
ATE397058T1 (en) IN VITRO RECONSTITUTED LAYERS OF THE HUMAN CORNEAL EPITHELIUM AND METHOD FOR THE PRODUCTION THEREOF
SE9804022D0 (en) Use of a parvovirus capsid particles in the inhibition of hematopoietic progenitor cells
WO2021173928A3 (en) Human alpha-galactosidase variants
Zhang et al. RSK-3 promotes cartilage regeneration via interacting with rpS6 in cartilage stem/progenitor cells
DE60020727D1 (en) COMPOSITION FOR PREVENTING AND TREATING TRANSPLANT DISCHARGE

Legal Events

Date Code Title Description
NUG Patent has lapsed